Table 1.

Marrow Hematopoietic Progenitor Cell Levels After the Administration of BAH-1, TPO, Control MoAb, or TPO plus BAH-1 to Myelosuppressed Mice

TreatmentCFU-MK (×10−3)BFU-E (×10−3) Experiment 1CFU-GM (×10−3) Experiment 1
Experiment 1Experiment 2Experiment 3
Control 2.0 ± 1.0 9.0 ± 1.0 
TPO 10.5 ± 0.5-150 3.0 ± 1.0-150 7.5 ± 1.0-150 7.0 ± 1.0-150 50.5 ± 9.5-150 
BAH-1 1.0 ± 0 2.0 ± 1.0 2.0 ± 1.0 2.5 ± 1.0 12.0 ± 1.0 
BAH-1 +  TPO 12.0 ± 1.0-150 4.5 ± 0.5-150 12.5 ± 1.0-150 7.5 ± 0.5-150 ND 
TreatmentCFU-MK (×10−3)BFU-E (×10−3) Experiment 1CFU-GM (×10−3) Experiment 1
Experiment 1Experiment 2Experiment 3
Control 2.0 ± 1.0 9.0 ± 1.0 
TPO 10.5 ± 0.5-150 3.0 ± 1.0-150 7.5 ± 1.0-150 7.0 ± 1.0-150 50.5 ± 9.5-150 
BAH-1 1.0 ± 0 2.0 ± 1.0 2.0 ± 1.0 2.5 ± 1.0 12.0 ± 1.0 
BAH-1 +  TPO 12.0 ± 1.0-150 4.5 ± 0.5-150 12.5 ± 1.0-150 7.5 ± 0.5-150 ND 

The results for femoral progenitors in each experiment represent the mean ± SEM of three animals in Experiments 1 and 2, whereas Experiment 3 included five animals in each treatment group.

Abbreviation: ND, not determined.

F0-150

P < .005 compared with control.

or Create an Account

Close Modal
Close Modal